Public health research, data analysis, and commentary on the global provision of sexual and reproductive health and rights; telemedicine and self-managed medical abortion; ethics, policy and payment.
Data obtained from five NHS Ambulance Trusts in England, show that emergency ambulance responses for complications arising after a medical abortion are three times higher for women using pills-by-post at home, compared to those who have their medical abortion in a clinic. Using our rights under the Freedom of Information Act, we asked each of... Continue Reading →
BPAS has reported that its abortion services are “under considerable pressure” and that the number of calls it has been receiving increased by about a third in the six months March to September this year. During the same period our volunteers were making mystery client calls to BPAS and MSI Reproductive Choices, and we found... Continue Reading →
Did you know that the Government and Abortion Providers routinely under report the rate of complications caused by abortion pills? Our freedom of information investigation reveals that less than 1-in-5 complications are being reported. DHSC Under Report. The official DHSC statistics for 2020 show a 1.1% complication rate for all medical abortions and only 0.3%... Continue Reading →
Medical abortion doesn't always work; it is well established that MA has an expected treatment failure rate of about 6%. Which means that as many as 1-in-17 pregnant women using abortion pills will subsequently need hospital treatment for complications arising from an incomplete abortion. Ranbaxy (UK) Limited is the manufacturer of Medabon, the mifepristone/misoprostol combination... Continue Reading →
Gynuity Health Projects, a pro-abortion activist organisation, recently published results from its own study into the safety and efficacy of telemedicine abortion. Two key findings are: Six percent of women using abortion pills at home, subsequently needed hospital treatment because of complications related to the abortion, a rate of 1-in-17.Four percent of women using abortion... Continue Reading →
In its SmPC (summaries of product characteristics), Ranbaxy states that there is a non-negligible risk of medical abortion treatment failure, as follows: The non-negligible risk of failure, which occurs in 4.5 to 7.8% of the cases, makes the follow-up visit mandatory in order to check that abortion is complete.The patient should be informed that surgical... Continue Reading →
Marie Stopes Australia (MSA) says that more than 5% of the medical abortions it provides, fail to complete. Meaning that 1-in-20 women will have fragments of the baby and/or placenta remaining in their womb after taking both sets of the tablets, mifepristone and misoprostol. These women will need to seek further treatment to prevent ongoing... Continue Reading →
On 25 May 2021, Public Health Scotland (PHS) released its official abortion statistics for the year ending December 2020. You may have already read that in 2020 there were a total of 13,815 abortions, the highest annual total since 2008, and that 36% of these were repeat abortions, which continues an increasing trend year-on-year. In this short... Continue Reading →
If you are going to use reduced waiting times to substantiate your preference for telemedicine abortion, then you need to make sure that you are comparing like-for-like. It is wrong to compare the elapsed time from first contact to in-clinic dispensing, with the time from first contact to posting the abortion pills; posting is not... Continue Reading →
Caroline Gazet, UK Clinical Director for MSI Reproductive Choices, says that she is both saddened and angered by the term ‘DIY abortion’. This made me smile. It is ironic for a senior member of the Marie Stopes team to complain about others using such terminology to describe abortion at-home when they themselves are fixated on... Continue Reading →
Percuity 